logo

Increased KI67 Immunostaining is Associated with Breast Cancer Aggressiveness

Authors

  • Dhafer A. Alghezi

    Microbiology Department, College of Medicine, University of Thi-Qar, Thi-Qar, 64001, Iraq

  • Rasha Aljawher

    Department of Histopathology and Forensic Medicine, College of Medicine, University of Thi-Qar, Thi-Qar, 64001, Iraq

  • Hameed Naeem Mosa

    Department of Histopathology and Forensic Medicine, College of Medicine, University of Thi-Qar, Thi-Qar, 64001, Iraq

DOI:

https://doi.org/10.30683/1929-2279.2025.14.19

Keywords:

Breast cancer, Grades, IHC, KI67, Tumor size

Abstract

Background: Breast cancer remains one of the most prevalent tumors among females worldwide, and current prognostic methods are limited in their ability to accurately predict tumor aggressiveness and long-term outcomes. KI67 is a nuclear protein marking active cell proliferation and is associated with tumor differentiation, growth, and breast cancer subtypes.

Objective: This study aims to assess KI67 in benign and malignant breast tissues and explore its potential association with clinical outcomes.

Methodology: Immunohistochemistry was used to assess KI67 staining in benign (n=57) and malignant (n=430) breast tissue samples. KI67 expression was then correlated with clinic opathological data, such as grade and stage, and breast cancer molecular subtypes.

Results: Increased KI67 was significantly found in breast carcinoma compared to benign tissues (P <0.0001). A positive association was observed between KI67 immunostaining and tumor grade (P <0.0001), tumor size (P0.007), and molecular subtype (P 0.002).No significant relationship was recognized between KI67 immunostaining and lymph node involvement.

Conclusion: KI67 might be involved in the aggressiveness of malignancy. Further research is needed to determine the significance of KI67 inbreast carcinoma and its potential as a biomarker for breast cancer progression.

References

[1] Abdelaziz LA, Ebian HF, Harb OA, Nosery Y, Taha HF, Nawar N. Clinical significance of cytokeratin 19 and OCT4 as survival markers in non-metastatic and metastatic breast cancer patients. Contemp Oncol (Pozn) 2022; 26(1): 78-87.

[2] Smolarz B, Nowak AZ, Romanowicz H. Breast Cancer-Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature). Cancers (Basel) 2022; 14(10).

[3] Zhang Y, Ji Y, Liu S, Li J, Wu J, Jin Q, et al. Global burden of female breast cancer: new estimates in 2022, temporal trend and future projections up to 2050 based on the latest release from GLOBOCAN. Journal of the National Cancer Center 2025; 5(3): 287-96.

[4] Salih HH, Abd SY, Al-Kaseer E, Al-Diwan J. Cancer in Iraq, general view of annual report 2022. Journal of Contemporary Medical Sciences 2025; 10(6).

[5] Teichgraeber DC, Guirguis MS, Whitman GJ. Breast Cancer Staging: Updates in the AJCC Cancer Staging Manual, 8th Edition, and Current Challenges for Radiologists, From the AJR Special Series on Cancer Staging. AJR Am J Roentgenol 2021; 217(2): 278-90.

[6] van Dooijeweert C, van Diest PJ, Ellis IO. Grading of invasive breast carcinoma: the way forward. Virchows Arch 2022; 480(1): 33-43.

[7] Popa MT, Nodiţi A, Peleaşă TM, Stoleru S, Blidaru A. Breast Cancer: A Heterogeneous Pathology. Prognostic and Predictive Factors - A Narrative Review. Chirurgia (Bucur) 2025; 120(1): 32-47.

[8] Alghezi DA, P W, BeresfordM, R B, J M, D CA. Reduced β-catenin immunostaining in prostate cancer and negatively associated with poorly differentiated Gleason grades. Kerbala journal of pharmacy and pharmaceutical science 2021; 1(19): 179-95.

[9] Alalwany O, Alghezi DA, Aljawher RQ, Harb A. Increased CD3 immunostaining associated with high grade and tumor size in colorectal carcinoma. Egyptian Journal of Medical Microbiology 2025; 34(1): 205-12.

[10] Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast cancer. Nature Reviews Disease Primers 2019; 5(1): 66.

[11] Davey MG, Hynes SO, Kerin MJ, Miller N, Lowery AJ. Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer. Cancers (Basel) 2021; 13(17).

[12] Wang W, Gong Y, Chen B, Guo H, Wang Q, Li J, et al. Quantitative immunohistochemistry analysis of breast Ki67 based on artificial intelligence. Open Life Sci 2024; 19(1): 20221013.

[13] Probert J, Dodwell D, Broggio J, Charman J, Dowsett M, Kerr A, et al. Ki67 and breast cancer mortality in women with invasive breast cancer. JNCI Cancer Spectr 2023; 7(5).

[14] Aleskandarany MA, Green AR, Benhasouna AA, Barros FF, Neal K, Reis-Filho JS, et al. Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer. Breast Cancer Research 2012; 14(1): R3.

[15] Höller A, Nguyen-Sträuli BD, Frauchiger-Heuer H, Ring A. "Diagnostic and Prognostic Biomarkers of Luminal Breast Cancer: Where are We Now?" Breast Cancer (Dove Med Press) 2023; 15: 525-40.

[16] Sandilya U, K M. Expression of Ki-67 in Invasive Breast Carcinoma and Its Correlation With Different Clinicopathological Features. Cureus 2024; 16(9): e69820.

[17] Alghezi D, Aljawher R, Musawi S. Increased CD73 expression is associated with poorly differentiated Gle ason score and tumor size in prostate cancer. J Adv Biotechnol Exp Ther 2023; 6(1): 161.

[18] Soliman NA, Yussif SM. Ki-67 as a prognostic marker according to breast cancer molecular subtype. Cancer Biology and Medicine 2016; 13(4): 496-504.

[19] Mahdi AS, Ibrahim HH, Mohammed AA. Ki-67 Expression as an Indicator of Invasiveness in Patients with Breast Cancer. Medical Journal of Babylon 2018; 15(4): 271-5.

[20] Hoda SA, Brogi E, Koerner FC, Rosen PP. Rosen's breast pathology: Fourth edition2014. 1-1400 p.

[21] Verdial FC, Etzioni R, Duggan C, Anderson BO. Demo-graphic changes in breast cancer incidence, stage at dia-gnosis and age associated with population-based mammo-graphic screening. J Surg Oncol 2017; 115(5): 517-22.

[22] Hendrick RE, Monticciolo DL, Biggs KW, Malak SF. Age distributions of breast cancer diagnosis and mortality by race and ethnicity in US women. Cancer 2021; 127(23): 4384-92.

[23] Kim JS, Lee JH, Yeon Y, An D, Kim SJ, Noh M-G, et al. Predicting Nottingham grade in breast cancer digital pathology using a foundation model. Breast Cancer Research 2025; 27(1): 58.

[24] Narod SA. Tumour size predicts long-term survival among women with lymph node-positive breast cancer. Curr Oncol 2012; 19(5): 249-53.

[25] Tonellotto F, Bergmann A, de Souza Abrahão K, de Aguiar SS, Bello MA, Thuler LCS. Impact of Number of Positive Lymph Nodes and Lymph Node Ratio on Survival of Women with Node-Positive Breast Cancer. Eur J Breast Health 2019; 15(2): 76-84.

[26] Wang J, Li B, Luo M, Huang J, Zhang K, Zheng S, et al. Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance. Signal Transduct Target Ther 2024; 9(1): 83.

[27] Feriancová M, Walter I, Singer CF, Gazdarica J, Pohlodek K. Expression of COX-2, p16, and Ki67 in the range from normal breast tissue to breast cancer. Neoplasma 2021; 68(2): 342-51.

[28] Tan P-H, Bay B-H, Yip G, Selvarajan S, Tan P, Wu J, et al. Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death. Modern Pathology 2005; 18(3): 374-81.

[29] Yousef E, Furrer D, Laperriere D, Tahir R, Mader S, Diorio C, et al. MCM2: An alternative to Ki-67 for measuring breast cancer cell proliferation. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2017; 30.

[30] Ma Q, Liu YB, She T, Liu XL. The Role of Ki-67 in HR+/HER2- Breast Cancer: A Real-World Study of 956 Patients. Breast Cancer (Dove Med Press) 2024; 16: 117-26.

[31] Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, et al. Assessment of Ki67 in breast cancer: recom-mendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 2011; 103(22): 1656-64.

[32] Inwald EC, Klinkhammer-Schalke M, Hofstädter F, Zeman F, Koller M, Gerstenhauer M, et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat 2013; 139(2): 539-52.

[33] Petrelli F, Viale G, Cabiddu M, Barni S. Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients. Breast Cancer Res Treat 2015; 153(3): 477-91.

[34] Nielsen TO, Leung SCY, Rimm DL, Dodson A, Acs B, Badve S, et al. Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 2021; 113(7): 808-19.

[35] Polley MY, Leung SC, McShane LM, Gao D, Hugh JC, Mastropasqua MG, et al. An international Ki67 reproducibility study. J Natl Cancer Inst 2013; 105(24): 1897-906.

[36] Sun J, Chen C, Wei W, Zheng H, Yuan J, Tu YI, et al. Associations and indications of Ki67 expression with clinicopathological parameters and molecular subtypes in invasive breast cancer: A population-based study. Oncol Lett 2015; 10(3): 1741-8.

[37] Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013; 24(9): 2206-23.

[38] Denkert C, Budczies J, von Minckwitz G, Wienert S, Loibl S, Klauschen F. Strategies for developing Ki67 as a useful biomarker in breast cancer. Breast 2015; 24 Suppl 2: S67-72.

[39] Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 2010; 7(5): e1000279.

[40] Denkert C, Loibl S, Müller BM, Eidtmann H, Schmitt WD, Eiermann W, et al. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Ann Oncol 2013; 24(11): 2786-93.

[41] Jumaah AS, Shaker RA, Al-Ali Z, Altoriah KMJ, Al-Quzweni A, Jumaah SS, et al. Immunohistochemical Breast Cancer Profiling Among Iraqi Women: Molecular Subtype Classification, Clinicopathology Associations, and Treatment-Decision Making Tools: A Cross-Sectional Study. Health Sci Rep 2025; 8(5): e70553.

[42] Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes RC, Cuzick J, et al. Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. JNCI: Journal of the National Cancer Institute 2011; 103(22): 1656-64.

Downloads

Published

2025-10-08

Issue

Vol. 14 (2025)

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite

Increased KI67 Immunostaining is Associated with Breast Cancer Aggressiveness. (2025). Journal of Cancer Research Updates, 14, 170-180. https://doi.org/10.30683/1929-2279.2025.14.19

Similar Articles

1-10 of 206

You may also start an advanced similarity search for this article.